Arecor Ltd

Arecor Ltd

Arecor Limited, located on the Cambridge Science Park, was established to provide formulation solutions to pharmaceutical and biotech companies developing drugs, vaccines, medical devices and diagnostics.

Telephone: +44 (0)1223 426 060
Address: Chesterford Research Park, Little Chesterford, Saffron Walden
Postcode: CB10 1XL
Country: United Kingdom
Website: http://www.arecor.com
Membership type:Corporate 6-20 (£250+VAT pa)

A UK-based leading formulation technology company delivering superior biopharmaceuticals via the innovative reformulation of proteins and peptides.

Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.

In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.

Arecor secures grant to advance co-formulation of critical pharmaceutical products

Innovate UK grant of nearly £1 million will be used to significantly advance Arecor’s proprietary co-formulation platform in the development of diabetes therapies that meet critical patient unmet needs.

18 June 2018Read in full

Arecor at World Congress’ Biologics Formulation and Drug Delivery Technologies Summit

Arecor Limited, the UK-based leading formulation technology company, focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides enabling the improved treatment of diabetes and other conditions, is pleased to announce its participation at The World Congress’ Biologics Formulation and Drug Delivery Technologies Summit, on 21st and 22nd May 2018, at the Hilton Hotel, Boston, Massachusetts, USA.

15 May 2018Read in full

Arecor launches new website

Arecor Ltd, the leading formulation technology company focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides to improve the treatment of diabetes and other conditions, is pleased to announce the launch of its new website.

10 January 2018Read in full

European patent on the horizon for Arecor’s proprietary technology

Arecor Ltd is pleased to announce the European Patent Office (EPO) has issued “Notice of Intention to Grant” for Arecor’s patent application protecting the Company’s proprietary technology used in the development of stable, low-viscosity formulations of highly concentrated protein therapeutics, including monoclonal antibodies such as trastuzumab or ustekinumab or fusion proteins such as abatacept.

8 January 2018Read in full

Arecor and JDRF announce successful pre-clinical development of diabetes treatment

Arecor and JDRF announce the successful pre-clinical development of stable rapid-acting, ultra-concentrated insulin for the significantly enhanced treatment of type 1 diabetes.

4 January 2018Read in full

Arecor’s vaccine stabilising formulation technology helps combat livestock diseases

Arecor Ltd, a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, ArestatTM, is pleased to announce that the Company, in partnership with GALVmed, has successfully applied its vaccine formulation technology to stabilise liquid formulations of vaccines to combat two major diseases of livestock in the developing world.

8 December 2017Read in full

Arecor strengthens the patent portfolio of its formulation technology

Notification of an ‘intention to grant’ a patent protecting Arecor’s novel approach to enabling stable liquid adenovirus formulations has been received from both the European and US patent offices.

7 November 2017Read in full

Arecor has been selected to appear in the 2016/2017 edition of The Parliamentary Review

“The Company features alongside The Prime Minister, The Rt Hon Theresa May MP, and a small number of outstanding organisations in the Technology edition”

4 October 2017Read in full

Arecor announces license agreement with global pharmaceutical company

Arecor Ltd (“the Company”), the leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides to improve the treatment of diabetes and other conditions, is pleased to announce that a global pharmaceutical and healthcare company, has exercised its license option to Arecor’s proprietary formulation technology, to develop differentiated biosimilar products.

3 October 2017Read in full

Arecor announces the inaugural formation of a global diabetes Scientific Advisory Board

Arecor Ltd, the leading formulation technology company, focused on developing superior biopharmaceuticals to improve the treatment of diabetes and other conditions, announces the inaugural formation of a Global Diabetes Scientific Advisory Board (SAB) to support the scientific, pre-clinical and clinical development of its proprietary superior diabetes products to better improve the quality of life of those living with diabetes.

12 September 2017Read in full

  1. 1
  2. 2
  3. 3